Location: Home> PRODUCTS

  • Components for blood collection tubes
  • High Quality APIs
  • Cosmetics Raw Materials
  • Additives for Microcolumn Gel Card
  • Medical Instruments

Lenalidomide

【Product Name】 Lenalidomide 

【CAS NO. 】 191732-72-6 

【Molecular Weight】 259.26062 

【Molecular Formula】 C13H13N3O3 

【Melting Point】 269-271°C 

【Density】 1.460±0.06 g/cm3 

【Assay】 ≥99%(HPLC) 

【Appearance】 White to yellow crystalline powder 

【Package】 1g-1kg/Aluminum foil bag, as per your request. 

【Synonyms】 (3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione 

【Product Category】 API; Intermediates & Fine Chemicals; Pharmaceuticals

Product Details

【Usage & Synthesis】 

Lenalidomide is an anti-tumor drug developed by Celgene biopharmaceutical company in the United States. Its chemical structure is similar to thalidomide, and it has multiple effects such as anti-tumor, immune regulation and anti-angiogenesis. It can inhibit the secretion of proinflammatory cytokines and increase the secretion of anti-inflammatory cytokines in peripheral blood monocytes.In vitro tests showed that the drug inhibited proliferation of certain cell lines such as Namalwa cells.Leinalidomide inhibited the growth of multiple myeloma cells and MM1S cells in patients. In addition, this product can also inhibit the expression of cox-2 (cox-2), but it has no effect on cox-1.Two multicentre randomized, blind, placebo-controlled clinical studies evaluated the safety and efficacy of leinalidomide in multiple myeloma. The main endpoints of the studies were disease progression time (TTP) interim analysis, and the TTP in the combination group was significantly superior to that in the dexamethasone group.Recent clinical studies have shown that, in addition to treating MDS and MM, leidomide is effective in treating myeloma, leukemia, metastatic renal cell carcinoma, solid tumor, primary systemic amyloidosis, and systemic myelofibrosis with myelogenesis.Lenalidomide is a new generation of derivatives of thalidomide, but it has not been found to have teratogenic toxicity and is 100 times more effective than thalidomide.According to phase iii clinical trials, lenalidomide is currently the most effective treatment for multiple myeloma, extending survival by more than three years in more than half of patients.It was also the only drug that was effective in the treatment of myelodysplastic syndrome (MDS), and clinical results showed that 64% of MDS patients treated with nalidomide did not need blood transfusions to treat MDS. 

>>>> Our products are only raw materials for drugs or industry and can't be used for human or animals directly.

 

【Product Inquiry】

>> 24hours on line service, please contact us if you need further information; 

>> Promptly delivery: 1-3days after payment, FedEx, DHL, TNT , by air or sea; 

>> Best price and best quality for small scale (1kg) to commercial quantities.

>> We take research and development, technology innovation and scientific quality management as our core philosophy, high quality, fast delivery, competitive price and advanced technical services make us your preferred supplier. We sincerely look forward to cooperating with you in the future. 


【Contact us】

                                ******We are your partner!******

 Improve Medical Technology(Nanxiong) Co.,Ltd. 

NO.33,Ping-An Road 1, Fine Chemical Industry Park of Nanxiong City Shaoguan, Guangdong, P.R.C 

Tel: +86-(0)751-3836997 (Overseas Business Dept.) 

Tel: +86-(0)751-3802286 (Domestic Sales Dept.) 

Fax: +86-(0)751-3836882 

Website: www.nximprove-medical.com 

Email: nxyp-sales@improve-medical.com